Anaemia is defined as a decrease in the total amount of hemoglobin or the number of red blood cells. Iron deficiency anemia is a form of anaemia develops due to the lack of sufficient iron to form normal red blood cells. It is typically caused by inadequate intake of iron, chronic

blood loss, digestive problem and other systemic and metabolic diseases. Present study was designed to evaluate the efficacy and safety of Unani drug Sharbat-e-Faulad in cases of anaemia. Haematological and biochemical studies were carried out to determine the efficacy and safety of the test drug. In haematological studies a significant increase in the level of haemoglobin (19.79%), Red blood corpuscles (18.94%), Total Leucocytes counts (15.6%) Packed Cell Volume (14.3%) and Mean Cell Haemoglobin Concentration (4.51%) (P<0.001) were observed. It was also found to reduce the level of Erythrocyte Sedimentation Rate (ESR) by 28.04% (P<0.001) (Table-2 & 3).

In Biochemical studies for liver function test, some patients showed decreased level of enzyme, while same enzyme was found increased in other patients but the deviation of either side was found within the normal range (Table-4, 5 & 6). Similarly, no significant change was observed on the two parameters of kidney function as the blood urea and serum creatinine levels were also found not to exceed the normal range.

It was, therefore, concluded that Sharbat-e-Faulad is a safe and effective haematinic drug and can be used in the patients of anaemia.